|
|
|
|
|
20.08.26 - 20:15
|
SIMCERE PHARMA Proposes Share Buyback with Funding Cap of RMB1B (AAStocks)
|
|
|
SIMCERE PHARMA (02096.HK) announced that it has resolved to exercise its authorization to repurchase shares on the open market at appropriate times, with a total amount not exceeding RMB1 billion. (de/d)~AASTOCKS Financial NewsWebsite: www.aastocks.comThis article was automatically translated by AI, the Chinese version should be......
|
|
|
20.08.26 - 20:15
|
Results: SIMCERE PHARMA Interim Net Profit RMB829 million Up 37.9% (AAStocks)
|
|
|
SIMCERE PHARMA (02096.HK) announced its interim results for the six months ended June 2026. Revenue was RMB4.58 billion, up 27.8% YoY. Net profit was RMB829 million, increasing 37.9%, mainly due to growth in revenue from innovative drugs and licensing income. EPS was RMB0.32. No dividend was declared. (d)~AASTOCKS Financial News......
|
|
|
31.07.26 - 03:45
|
Alert: SIMCERE PHARMA Forecasts Interim Net Profit to Soar Up to 43% YoY (AAStocks)
|
|
|
SIMCERE PHARMA (02096.HK) issued a positive profit alert, expecting net profit for the six months ended June 2026 to reach approximately RMB810-860 million, compared with the restated net profit of approximately RMB601 million in the corresponding period of 2025, representing a YoY increase of approximately 34.8-43.1%. In additi......
|
|
|
15.06.26 - 12:00
|
Simcere and Stanford partner to develop IPF therapies (PBR)
|
|
|
Under the deal, Simcere will provide funding for exploratory research on a first-in-class novel molecule in the respiratory field. If the research is successful, Simcere will have the
The post Simcere and Stanford partner to develop IPF therapies appeared first on Pharmaceutical Business review....
|
|
|
15.06.26 - 04:30
|
SIMCERE PHARMA 's SIM0689 Approved for Clinical Trials (AAStocks)
|
|
|
SIMCERE PHARMA (02096.HK) announced that SIM0689, a PD-1/VEGF-targeting bispecific antibody independently developed by the group, has received a Clinical Trial Approval Notice from the National Medical Products Administration (NMPA) of China. The drug is planned to commence clinical trials for advanced solid tumors.SIM0689 is a ......
|
|
|
|
|
|
|
|
|
|
|
01.06.26 - 14:03
|
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026 (GlobeNewswire EN)
|
|
|
BELTSVILLE, Md., June 01, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, and Simcere Zaiming Pharmaceutical Co., Ltd., (Simcere Zaiming) an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096), today announced the presentation of positive Phase 1 dose escalation data for SIM0505 at the American Society for Clinical Oncology (ASCO 2026) in Chicago, IL (poster #246). SIM0505 is an investigational antibody drug conjugate (ADC) targeting Cadherin-6 (CDH6) with a proprietary topoisomerase 1 inhibitor (TOPOi) payload. NextCure plans to host a virtual KOL Event on Tuesday, June 2, 2026 (register here) to review these data....
|
|
|
|
|
04.05.26 - 13:09
|
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers (GlobeNewswire EN)
|
|
|
BELTSVILLE, Md., May 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer and Simcere Zaiming Pharmaceutical Co., Ltd., (Simcere) an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096), today announced initiation of the dose optimization portion of the Phase 1 study of SIM0505, focusing on patients with platinum-resistant ovarian cancer. SIM0505 is an investigational antibody drug conjugate (ADC) comprised of an antibody that targets Cadherin-6 (CDH6) and a proprietary topoisomerase 1 inhibitor (TOPOi) payload....
|
|
|
30.04.26 - 11:00
|
SIMCERE PHARMA Leudebacimab NDA Accepted for Review (AAStocks)
|
|
|
SIMCERE PHARMA (02096.HK) announced that the resubmitted New Drug Application (NDA) for the innovative drug leudebacimab, developed in collaboration with Hong Kong Korno Biotherapeutics Company Limited, has been accepted for review by the National Medical Products Administration (NMPA). The drug is intended for the treatment of ......
|
|
|
|
|
|
|
|
|
10.03.26 - 14:03
|
Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting (GlobeNewswire EN)
|
|
|
SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect, or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that the results of a Phase 3 study of rademikibart in moderate-to-severe atopic dermatitis (AD) conducted by the Company's partner in China, Simcere Pharmaceutical Co., Ltd. (Simcere), will be presented in the Late-Breaking Research session at the 2026 AAD Annual Meeting, which takes place March 27-31, 2026, in Denver, Colorado....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
